Skip to main content
Graduate School of Biomedical Sciences

Recent Publications from the Degterev Lab

Degterev A, Ofengeim D, Yuan J. 2019. Targeting RIPK1 for the treatment of human diseases. Proc Natl Acad Sci USA. Epub ahead of print. Abstract

Saleh D, Degterev A. 2018. Chemical library screens to identify pharmacological modulators of necroptosis. Methods Mol Biol. 1857: 19-33. Abstract

Hrdinka M, Schlicher L, Dai B, Pinkas DM, Bufton JC, Picaud S, Ward JA, Rogers C, Suebsuwong C, Nikhar S, Cuny GD, Huber KV, Filippakopoulos P, Bullock AN, Degterev A, Gyrd-Hansen M. 2018. Small molecule inhibitors reveal an indispensable scaffolding role of RIPK2 in NOD2 signaling. EMBO J Epub ahead of print. Abstract

Tabtieng T, Degterev A, Gaglia MM. 2018. Caspase-dependent suppression of type I interferon signaling promotes KSHV lytic replication. J Virol. Epub ahead of print.  Abstract

Saleh D, Degterev A. 2018. Chemical library screens to identify pharmacological modulators of necroptosis. Methods in Molecular Biology: Programmed Necrosis. Springer Publishing, Berlin. ISBN 978-1-4939-8753-5.

von Mässenhausen A, Tonnus W, Himmerkus N, Parmentier S, Saleh D, Rodriguez D, Ousingsawat J, Ang RL, Weinberg JM, Sanz AB, Ortiz A, Zierleyn A, Becker JU, Baratte B, Desban N, Bach S, Schiessl IM, Nogusa S, Balachandran S, Anders HJ, Ting AT, Bleich M, Degterev A, Kunzelmann K, Bornstein SR, Green DR, Hugo C, Linkermann A. 2018. Phenytoin inhibits necroptosis. Cell Death Dis. 9:359. Abstract

Suebsuwong C, Pinkas DM, Ray SS, Bufton JC, Dai B, Bullock AN, Degterev A, Cuny GD. 2018. Activation loop targeting strategy for design of receptor-interacting protein kinase 2 (RIPK2) inhibitors. Bioorg Med Chem Lett. 28: 577-583. Abstract

Pattni BS, Jhaveri A, Dutta I, Baleja JD, Degterev A, Torchilin V. 2017. Targeting energy metabolism of cancer cells: Combined administration of NCL-240 and 2-DG. Int J Parm. Epub ahead of print.  Abstract

Lule S, Wu L, McAllister LM, Edmiston WJ 3rd, Chung JY, Levy E, Zheng Y, Gough PJ, Bertin J, Degterev A, Lo EH, Whalen MJ. 2017. Genetic inhibition of receptor interacting protein kinase-1 reduces cell death and improves functional outcome after intracerebral hemorrhage in mice. Stroke Epub ahead of print. Abstract

Saleh D, Najjar M, Zelic M, Shah S, Nogusa S, Polykratis A, Paczosa MK, Gough PJ, Bertin J, Whalen M, Fitzgerald KA, Slavov N, Pasparakis M, Balachandran S, Kelliher M, Mecsas J, Degterev A. 2017. Kinase activities of RIPK1 and RIPK3 can direct IFN-β synthesis induced by lipopolysaccharide. J Immunol. 198: 4435-4447.  Abstract

Wegner KW, Saleh D, Degterev A. 2017. Complex pathologic roles of RIPK1 and RIPK3: Moving beyond necroptosis. Trends Pharmacol Sci. 38: 202-225.  Abstract

Pattni BS, Nagelli SG, Aryasomayajula B, Deshpande PP, Kulkarni A, Hartner WC, Thakur G, Degterev A, Torchilin VP. 2016. Targeting of micelles and liposomes loaded with the pro-apoptotic drug, NCL-240, into NCI/ADR-RES cells in a 3D spheroid model. Pharm Res. 33: 2540-2551.  Abstract

Najjar M*, Saleh D*, Zelic M, Nogusa S, Shah A, Tai A, Finger JN, Polykratis A, Gough PJ, Bertin J, Whalen M, Pasparakis, Balachandran S, Kelliher M, Poltorak A, Degterev A. 2016. RIPK1 and RIPK3 kinases promote cell death-independent inflammation by TLR4-TRIF. Immunity. 45: 46-59. * equal contribution. Abstract

Degterev A, Linkermann A. 2016. Generation of small molecules to interfere with regulated necrosis. Cell Mol Life Sci. 73: 2251-2267.  Abstract

Riehle R, Pattni B, Jhaveri A, Kulkarni A, Thakur G, Degterev A, Torchilin V. 2016. Combination nanopreparations of a novel proapoptotic drug - NCL-240, TRAIL and siRNA. Pharm Res. 33: 1587-1601.  Abstract

Sriraman SK, Geraldo V, Luther E, Degterev A, Torchilin V. 2015. Cytotoxicity of PEGylated liposomes co-loaded with novel pro-apoptotic drug NCL-240 and the MEK inhibitor cobimetinib against colon carcinoma in vitro. J Control Release 220: 160-168.  Abstract

Bullock AN, Degterev A. 2015. Targeting RIPK1,2,3 to combat inflammation. Oncotarget. 6: 34057-34058. Abstract

Saleh D, Degterev A. 2015. Emerging roles for RIPK1 and RIPK3 in pathogen-induced cell death and host immunity. Curr Topics Microbiol Immunol. Epub ahead of print.   Abstract

Canning P, Ruan Q, Schwerd T, Hrdinka M, Maki JL, Saleh D, Suebsuwong C, Ray S, Brennan PE, Cuny GD, Uhlig HH, Gyrd-Hansen M, Degterev A, Bullock AN. 2015. Inflammatory signaling by NOD-RIPK2 ss inhibited by clinically relevant type II kinase inhibitors. Chem Bio. 22: 1174-1184. Abstract

Najjar M, Suebsuwong C, Ray SS, Thapa RJ, Maki JL, Nogusa S, Shah S, Saleh D, Gough PJ, Bertin J, Yuan J, Balachandran S, Cuny GD, Degterev A. 2015. Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1. Cell Rep. 10: 1850-1860. Abstract

Degterev A, Zhou W, Maki JL, Yuan J. 2014. Assays for necroptosis and activity of RIP kinases. Methods Enzymol. 545:1-33. Abstract

Zhu X, Park J, Golinski J, Qiu J, Khuman J, Lee CC, Lo EH, Degterev A, Whalen MJ. 2014. Role of Akt and mammalian target of rapamycin in functional outcome after concussive brain injury in mice. J Cereb Blood Flow Metab. 34: 1531-1539. Abstract

Dvoriantchikova G, Degterev A, Ivanov D. 2014. Retinal ganglion cell (RGC) programmed necrosis contributes to ischemia-reperfusion-induced retinal damage. Exp Eye Res. 123: 1-7. Abstract

Schworer SA, Smirnova II, Kurbatova I, Bagina U, Churova M, Fowler T, Roy AL, Degterev A, Poltorak A. 2014. Toll-like receptor-mediated downregulation of the deubiquitinase CYLD protects macrophages from necroptosis in wild-derived mice. J Biol Chem. 289: 14422-14433. Abstract

Newton K, Hildebrand JM, Shen Z, Rodriguez D, Alvarez-Diaz S, Petersen S, Shah S, Dugger DL, Huang C, Auwerx J, Vandenabeele P, Green DR, Ashkenazi A, Dixit VM, Kaiser WJ, Strasser A, Degterev A, Silke J. 2014. Is SIRT2 required for necroptosis? Nature 506: E4-E6. Abstract